LIORESAL INTRATHECAL Rx
Generic Name and Formulations:
Baclofen 50mcg/mL, 500mcg/mL, 2000mcg/mL; for intrathecal inj; preservative-free.
Indications for LIORESAL INTRATHECAL:
Severe spasticity of cerebral or spinal origin, when oral baclofen is not appropriate.
Adults and Children:
<4yrs: not established. ≥4yrs: Give test dose 1st by intrathecal inj via spinal catheter or lumbar puncture (see full labeling for dose and timing; use 50mcg/mL syringe). Dose titration: see full labeling. Maintenance: titrate individually; use lowest effective dose; maintain muscle tone possibly close to normal. Spinal cord origin: usually 300–800mcg/day. Cerebral origin: usually 90–703mcg/day. Avoid abrupt cessation (may be severe/fatal); closely monitor pump, alarms, and refill schedule; wean orally-administered antispasticity drugs carefully.
Not for IV, IM, SC or epidural administration.
Do not discontinue abruptly; may result in high fever, altered mental status, rebound spasticity, muscle rigidity. Have resuscitative equipment and trained personnel available. Apparent risk patients (eg, spinal cord injury at T-6 or higher, communicative impairment, history of withdrawal symptoms): closely monitor infusion system, dosing schedule, refills, pump alarms, clinical signs of withdrawal or overdose. Do not use chronically if test dose ineffective. For chronic dosing use approved pump (eg, Medtronic SynchroMed Infusion System). Allow at least one year after traumatic brain injury before starting. Infections. Psychosis. Schizoaffective disorders. Confusion. Autonomic dysreflexia. Renal impairment. Hospitalize immediately if pump malfunction suspected. Pregnancy (Cat.C). Nursing mothers: not recommended.
Muscle relaxant (central), antispastic agent.
Hypotension, dyspnea with morphine. Additive CNS depression with alcohol, other CNS depressants. Do not mix with other drugs in pump or catheter.
Hypotonia, somnolence, dizziness, nausea, vomiting, paresthesia, headache, convulsion, hypotension, agitation, constipation, leukocytosis, chills, urinary retention, coma, drowsiness, psychosis, confusion; CNS depression, cardiovascular collapse, respiratory failure; others.
Single use ampules—1; Refill Kits—1, 2 (w. ampules and supplies)
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics